Coursework I – Parasitology 2019

Sample Answer

Critical Review of “Mutations in Plasmodium falciparum Actin‑Binding Protein Coronin Confer Reduced Artemisinin Susceptibility”

Introduction

The study addresses a significant concern in global health: the emergence of reduced susceptibility to artemisinin (ART) in Plasmodium falciparum. While mutations in the pfKelch13 gene have been well‑documented in Southeast Asia, the authors investigate alternate molecular pathways—specifically mutations in the actin‑binding protein coronin (pfcoronin) in African parasite isolates. This critique summarises the approach and findings, evaluates strengths and weaknesses, and considers implications for research and malaria control.

Summary of Key Findings

Demas et al. (2018) generated ART‑tolerant parasite lines in vitro from two West African isolates (Pikine and Thiès, Senegal) by long‑term exposure to increasing concentrations of dihydroartemisinin (DHA). The authors observed elevated ring‑stage survival assay (RSA) rates in the selected lines (≈7–9 %) compared with parental lines (<1 %). Whole‑genome sequencing revealed 10 mutations across seven genes; the pfcoronin gene was found mutated in both independent selected lines. Functional validation via CRISPR/Cas9 gene editing introduced specific pfcoronin mutations (G50E, R100K, E107V) into parental lines, resulting in significantly increased RSA survival, confirming that pfcoronin mutations are sufficient to reduce ART susceptibility. Importantly, the pfkelch13 locus remained wild‑type in these lines, suggesting a pfkelch13‑independent mechanism of ART resistance.

The authors propose that coronin (with a WD40‑propeller domain) may share structural similarity to Kelch13 and might affect parasite sensitivity by influencing actin‑mediated endocytosis of host haemoglobin, thus reducing haem‑mediated activation of ART. They note that natural polymorphisms of pfcoronin exist in African populations but the specific mutations engineered are not yet found in field isolates, leaving open the question of clinical relevance.

Critical Analysis

Strengths

1. Novelty and significance: The paper advances the field by identifying a second gene (pfcoronin) associated with reduced ART susceptibility, thereby broadening understanding of resistance beyond Kelch13.

2. Rigorous methodology: The long‑term in vitro selection over ~4 years, sequencing, and functional validation via CRISPR‑based gene editing lend robustness to the findings.

3. Clear phenotypic linkage: Elevated RSA survival in edited clones provides strong evidence of causality rather than mere association.

4. Relevance to African parasite context: Since Kelch13 mutations are rare in Africa, investigating alternate mechanisms is highly relevant for surveillance.

Limitations

1. In vitro versus clinical relevance: The parasites were selected in vitro under artificial drug pressure; the engineered mutations have not (as of publication) been identified in field populations, limiting immediate public‑health applicability. The authors themselves note this gap.

2. Genetic background effects: The study shows that background parasite genotype influences the phenotypic expression of pfcoronin mutations, yet full delineation of interacting loci remains lacking. Later work (e.g., Sharma et al. 2020) shows that pfkelch13 presence can mask pfcoronin effects.

3. Mechanistic ambiguity: While coronin is implicated in actin binding and endocytosis, the precise biochemical pathway by which the mutations reduce ART activation remains speculative rather than fully elucidated.

4. Selection bias: The selection regime may favour mutations with fitness trade‐offs not sustainable in natural transmission settings; hence, mutants may not spread widely in endemic populations.

Implications and Future Directions

The discovery of pfcoronin‑mediated reduced ART susceptibility has important implications: (a) Surveillance systems must widen molecular marker panels beyond pfkelch13; (b) Drug‑resistance mechanisms may be multigenic and context‑dependent; (c) Understanding the actin/endocytosis pathway may offer new therapeutic targets. Future research should include large‑scale field surveys in Africa to detect pfcoronin variants, functional studies in vivo, and exploration of combined mutations (e.g., pfcoronin + pfkelch13) to assess additive or synergistic effects.